Edwards Lifesciences (NYSE:EW) has seen a flurry of activity with multiple instances of shares being bought and sold by various companies and investors. For instance, Bellevue Group AG, State Street Corp, Nebula Research & Development LLC, and Glenview Trust Co. are among several entities that have sold significant quantities of
EW shares. On the other hand, companies like Banque Transatlantique SA, Elevatus Wealth Management, DZ BANK AG, and Bank of Nova Scotia have expanded their EW holdings. Edwards Lifesciences has projected optimism for its future performance, notably adjusting its 2025-2026 outlook, and signaling expected growth in Transcatheter Mitral and Tricuspid Therapies (
TMTT). Furthermore, the company welcomed the newly updated guidelines for Severe Aortic Stenosis. Detailed comparisons of Edwards Lifesciences' recent performance to other medical device stocks reveal it as an attractive investment option. Expectations are high for the company's upcoming earnings reports, shaped in part by its strong Q1 results in 2025.
Price targets for the corporation have also been raised by several financial institutions, indicating an optimistic market sentiment.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sun, 14 Dec 2025 00:25:47 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 6
